Unknown

Dataset Information

0

4-Hydroxyglutamate is a novel predictor of pre-eclampsia.


ABSTRACT: BACKGROUND:Pre-term pre-eclampsia is a major cause of maternal and perinatal morbidity and mortality worldwide. A multi-centre randomized-controlled trial has shown that first-trimester screening followed by treatment of high-risk women with aspirin reduces the risk of pre-term pre-eclampsia. However, the biomarkers currently employed in risk prediction are only weakly associated with the outcome. METHODS:We conducted a case-cohort study within the Pregnancy Outcome Prediction study to analyse untargeted maternal serum metabolomics in samples from 12, 20, 28 and 36?weeks of gestational age (wkGA) in women with pre-eclampsia delivering at term (n?=?165) and pre-term (n?=?29), plus a random sample of the cohort (n?=?325). We used longitudinal linear mixed models to identify candidate metabolites at 20/28?wkGA that differed by term pre-eclampsia status. Candidates were validated using measurements at 36?wkGA in the same women. We then tested the association between the 12-, 20- and 28-wkGA measurements and pre-term pre-eclampsia. We externally validated the association using 24- to 28-wkGA samples from the Born in Bradford study (25 cases and 953 controls). RESULTS:We identified 100 metabolites that differed most at 20/28?wkGA in term pre-eclampsia. Thirty-three of these were validated (P?

SUBMITTER: Sovio U 

PROVIDER: S-EPMC7124498 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

4-Hydroxyglutamate is a novel predictor of pre-eclampsia.

Sovio Ulla U   McBride Nancy N   Wood Angela M AM   Masconi Katya L KL   Cook Emma E   Gaccioli Francesca F   Charnock-Jones D Stephen DS   Lawlor Debbie A DA   Smith Gordon C S GCS  

International journal of epidemiology 20200201 1


<h4>Background</h4>Pre-term pre-eclampsia is a major cause of maternal and perinatal morbidity and mortality worldwide. A multi-centre randomized-controlled trial has shown that first-trimester screening followed by treatment of high-risk women with aspirin reduces the risk of pre-term pre-eclampsia. However, the biomarkers currently employed in risk prediction are only weakly associated with the outcome.<h4>Methods</h4>We conducted a case-cohort study within the Pregnancy Outcome Prediction stu  ...[more]

Similar Datasets

| S-EPMC2670320 | biostudies-literature
2019-11-25 | GSE125460 | GEO
| S-EPMC4407242 | biostudies-literature
| S-EPMC5891938 | biostudies-literature
| PRJNA516433 | ENA
| S-EPMC6868499 | biostudies-literature
| S-EPMC4943502 | biostudies-literature
| S-EPMC3852136 | biostudies-literature
| S-EPMC5082890 | biostudies-literature
| S-EPMC8074755 | biostudies-literature